Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.SSE: 603707

Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary

· Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

On 6ix: 6ix.com/news/nanjing-king-friend-biochemical-pharmaceutical-co-ltdannouncement-on-obtaining-us-fda-approval-for-adalimumab-injection-of-subsidiary

Release

Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix

Earlier from Nanjing King-friend Biochemical Pharmaceutical

Later from Nanjing King-friend Biochemical Pharmaceutical

All Nanjing King-friend Biochemical Pharmaceutical news releases